Recent Updates
Recently added Catalysts
QTRX Positive Sentiment Score: 75/100

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows

Wednesday, May 6, 2026 1 min read
Key Takeaway: Lucent Diagnostics has partnered with Tempus AI to enhance Alzheimer's disease detection through a blood-based biomarker panel. This collaboration aims to integrate the testing into clinical workflows, leveraging AI technology to improve precision medicine. The initiative is expected to broaden access to this novel testing method, potentially benefiting early diagnosis and treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to improve Alzheimer's detection accuracy.
  • Integration of AI technology enhances precision medicine.
  • Broader access to blood-based biomarker testing is expected.

Full Press Release Details

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing

Frequently Asked Questions

What is the purpose of the collaboration?

The collaboration aims to improve detection accuracy for Alzheimer's disease through blood-based biomarker testing.

Who are the companies involved in the collaboration?

The collaboration involves Lucent Diagnostics and Tempus AI Inc.

How will the testing be integrated into clinical workflows?

Tempus AI will build a care gap program to integrate the biomarker testing into clinical workflows.

What technology is being utilized in this partnership?

The partnership leverages AI technology to advance precision medicine in Alzheimer's detection.

Tags: QTRX Viatris Investor Conferences Healthcare Lucent Diagnostics Tempus AI Alzheimer's disease biomarker panel precision medicine
Last updated: May 6, 2026